Welcome to LookChem.com Sign In|Join Free

CAS

  • or
Warfarin, also known as Coumadin, is a medication that belongs to the class of anticoagulants, or blood thinners. It possesses the ability to inhibit the production of certain proteins necessary for blood clotting, thereby reducing the risk of blood clots forming in the blood vessels. Due to its anticoagulant properties, Warfarin is a crucial pharmaceutical for managing various conditions related to blood clotting.

81-81-2 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 81-81-2 Structure
  • Basic information

    1. Product Name: Warfarin
    2. Synonyms: SAKARAT;PROLIN(R);WARF COMPOUND 42(R);WARF(R);Warfarat;WARFARIN;ZOOCOUMARIN;4-HYDROXY-3-(3-OXO-1-PHENYLBUTYL)COUMARIN
    3. CAS NO:81-81-2
    4. Molecular Formula: C19H16O4
    5. Molecular Weight: 308.33
    6. EINECS: 201-377-6
    7. Product Categories: Coumarins;INSECTICIDE;Intermediates & Fine Chemicals;Pharmaceuticals;Miscellaneous Compounds;Aromatics;Heterocycles;API;Cardiovascular APIs;Pharma
    8. Mol File: 81-81-2.mol
  • Chemical Properties

    1. Melting Point: 162-164 °C(lit.)
    2. Boiling Point: 356°C
    3. Flash Point: 2℃
    4. Appearance: Colorless/Crystalline
    5. Density: 1.1411 (rough estimate)
    6. Refractive Index: 1.4434 (estimate)
    7. Storage Temp.: 2-8°C
    8. Solubility: N/A
    9. PKA: 4.50±1.00(Predicted)
    10. Water Solubility: Practically insoluble
    11. Merck: 13,10097
    12. CAS DataBase Reference: Warfarin(CAS DataBase Reference)
    13. NIST Chemistry Reference: Warfarin(81-81-2)
    14. EPA Substance Registry System: Warfarin(81-81-2)
  • Safety Data

    1. Hazard Codes: T,T+,Xn,F
    2. Statements: 61-48/25-52/53-28-21-36-20/21/22-11
    3. Safety Statements: 53-45-61-52-36/37-28-26-16
    4. RIDADR: UN 2811 6.1/PG 1
    5. WGK Germany: 3
    6. RTECS: GN4550000
    7. HazardClass: 6.1(a)
    8. PackingGroup: I
    9. Hazardous Substances Data: 81-81-2(Hazardous Substances Data)

81-81-2 Usage

Uses

Used in Medical Applications:
Warfarin is used as an anticoagulant for the treatment and prevention of blood clots. It is particularly effective in reducing the risk of stroke in patients with conditions such as atrial fibrillation and those who have undergone heart valve replacement. The medication helps maintain a balance in the blood's clotting ability, preventing the formation of unwanted blood clots that can lead to serious health complications.
Used in Stroke Prevention:
In the medical industry, Warfarin is used as a preventive measure for stroke. It is prescribed to patients with atrial fibrillation, a condition characterized by an irregular and often rapid heart rate, which increases the risk of blood clots and stroke. By thinning the blood, Warfarin lowers the likelihood of clot formation and, consequently, the risk of stroke.
Used in Post-Surgical Care:
Following certain surgeries, such as heart valve replacement, Warfarin is used as a part of post-operative care. It helps prevent the formation of blood clots that can occur as a result of the surgery, ensuring the patient's recovery process is not compromised by clot-related complications.

Check Digit Verification of cas no

The CAS Registry Mumber 81-81-2 includes 5 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 2 digits, 8 and 1 respectively; the second part has 2 digits, 8 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 81-81:
(4*8)+(3*1)+(2*8)+(1*1)=52
52 % 10 = 2
So 81-81-2 is a valid CAS Registry Number.
InChI:InChI=1/C19H16O4/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22/h2-10,15,21H,11H2,1H3

81-81-2 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Cerilliant

  • (W-003)  Warfarin solution  1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material

  • 81-81-2

  • W-003-1ML

  • 366.21CNY

  • Detail

81-81-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name warfarin

1.2 Other means of identification

Product number -
Other names Warfarin

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:81-81-2 SDS

81-81-2Synthetic route

4-hydroxy[1]benzopyran-2-one
1076-38-6

4-hydroxy[1]benzopyran-2-one

1-Phenylbut-1-en-3-one
122-57-6

1-Phenylbut-1-en-3-one

Conditions
ConditionsYield
With C23H24N2O6S*Li(1+) In tetrahydrofuran; dimethyl sulfoxide at 0℃; for 48h; Reagent/catalyst; Michael Addition;99%
With lipase In water at 50℃; for 168h; Temperature; Michael Addition; Enzymatic reaction;99.1%
With N-ethyl-N,N-diisopropylamine In water for 20h; Michael Addition; Reflux;93%
warfarin
81-81-2

warfarin

Conditions
ConditionsYield
With polystyrene-divinylbenzene support prepared cyclohexanol as porogen with immobilized 1,5,7-triazabicyclo[4.4.0]dec-5-ene at 100℃; for 96h; Reagent/catalyst; Solvent; Temperature; Time; Michael Addition; Green chemistry;96%
With L-proline In dimethyl sulfoxide at 20℃; for 15h; Michael addition;85%
With rac-Pro-OH In dimethyl sulfoxide at 20℃; for 24h;80%
With cetyltrimethylammonim bromide; 1,4-dihydropyridine-enolate In water at 20℃; for 10h; Michael addition;50%
4-hydroxy[1]benzopyran-2-one
1076-38-6

4-hydroxy[1]benzopyran-2-one

2-phenylethanol
60-12-8

2-phenylethanol

D,L-valine
516-06-3

D,L-valine

warfarin
81-81-2

warfarin

Conditions
ConditionsYield
In dimethyl sulfoxide at 20℃; for 16h;84%
4-hydroxy[1]benzopyran-2-one
1076-38-6

4-hydroxy[1]benzopyran-2-one

warfarin
81-81-2

warfarin

Conditions
ConditionsYield
With cyclopentene In chlorobenzene; toluene at 100℃; for 8h; Inert atmosphere; regioselective reaction;83%
3-(phenyl-λ3-iodanylidene)chromane-2,4-dione
86795-49-5

3-(phenyl-λ3-iodanylidene)chromane-2,4-dione

(E)-benzalacetone
1896-62-4

(E)-benzalacetone

warfarin
81-81-2

warfarin

Conditions
ConditionsYield
In acetonitrile at 80℃; for 12h;76%
(+/-)-Warfarin 4-methyl ether
38063-51-3

(+/-)-Warfarin 4-methyl ether

warfarin
81-81-2

warfarin

Conditions
ConditionsYield
With boron tribromide In dichloromethane -78 up to 0 deg C;
2-methoxywarfarin
102077-97-4

2-methoxywarfarin

warfarin
81-81-2

warfarin

Conditions
ConditionsYield
With boron tribromide In dichloromethane -78 up to 0 deg C;
4-hydroxy[1]benzopyran-2-one
1076-38-6

4-hydroxy[1]benzopyran-2-one

water
7732-18-5

water

(E)-benzalacetone
1896-62-4

(E)-benzalacetone

warfarin
81-81-2

warfarin

4-hydroxy[1]benzopyran-2-one
1076-38-6

4-hydroxy[1]benzopyran-2-one

2-Methoxypropene
116-11-0

2-Methoxypropene

benzaldehyde
100-52-7

benzaldehyde

warfarin
81-81-2

warfarin

Conditions
ConditionsYield
Stage #1: 4-hydroxy[1]benzopyran-2-one; 2-Methoxypropene; benzaldehyde With ethylenediamine diacetic acid In 1,4-dioxane at 90℃; for 4h; tandem Knoevenagel-hetero-Diels-Alder reaction;
Stage #2: With hydrogenchloride; silica gel In water; trifluoroacetic acid at 20℃;
quat-ammonium salt

quat-ammonium salt

(E)-benzalacetone
1896-62-4

(E)-benzalacetone

warfarin
81-81-2

warfarin

Conditions
ConditionsYield
In water
benzaldehyde
100-52-7

benzaldehyde

warfarin
81-81-2

warfarin

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 1-n-butyl-3-methylimidazolim bromide; bovine serum albumin; tetrabutylammomium bromide / 4 h / 60 °C / Inert atmosphere; Enzymatic reaction
2: 48 h
View Scheme
Multi-step reaction with 2 steps
1: sodium hydroxide / water / Microwave irradiation
2: N-ethyl-N,N-diisopropylamine / water / 20 h / Reflux
View Scheme
Multi-step reaction with 2 steps
1: Fe3O4(at)L-proline/Pd2 NCs / 24 h / 70 °C / Sealed tube
2: water / 12 h / 100 °C
View Scheme
warfarin
81-81-2

warfarin

(1R,2S,5R)-menthyl chloroformate
14602-86-9

(1R,2S,5R)-menthyl chloroformate

Carbonic acid (1R,2S,5R)-2-isopropyl-5-methyl-cyclohexyl ester 2-oxo-3-(3-oxo-1-phenyl-butyl)-2H-chromen-4-yl ester

Carbonic acid (1R,2S,5R)-2-isopropyl-5-methyl-cyclohexyl ester 2-oxo-3-(3-oxo-1-phenyl-butyl)-2H-chromen-4-yl ester

Conditions
ConditionsYield
With TEA In 1,2-dichloro-ethane for 0.5h; Ambient temperature;100%
warfarin
81-81-2

warfarin

N-methoxylamine hydrochloride
593-56-6

N-methoxylamine hydrochloride

4-hydroxy-3-(3-(methoxyimino)-1-phenylbutyl)-2H-1-benzopyran-2-one
1103877-12-8

4-hydroxy-3-(3-(methoxyimino)-1-phenylbutyl)-2H-1-benzopyran-2-one

Conditions
ConditionsYield
With pyridine In methanol at 20℃; for 18h;99%
warfarin
81-81-2

warfarin

A

dehydrowarfarin
67588-18-5

dehydrowarfarin

B

C18H12O3

C18H12O3

Conditions
ConditionsYield
With copper(l) iodide In pyridine at 55 - 60℃; for 5h; air;A 98%
B n/a
warfarin
81-81-2

warfarin

Methylenetriphenylphosphorane
19493-09-5

Methylenetriphenylphosphorane

4-hydroxy-3-(3-methyl-1-phenyl-3-butenyl)-2H-1-benzopyran-2-one
92824-18-5

4-hydroxy-3-(3-methyl-1-phenyl-3-butenyl)-2H-1-benzopyran-2-one

Conditions
ConditionsYield
In tetrahydrofuran; dimethyl sulfoxide95%
In tetrahydrofuran; dimethyl sulfoxide65%
warfarin
81-81-2

warfarin

3-nitro-benzaldehyde
99-61-6

3-nitro-benzaldehyde

4-hydroxy-3-[5-(3-nitro-phenyl)-3-oxo-1-phenyl-pent-4-enyl]-chromen-2-one
1189759-41-8

4-hydroxy-3-[5-(3-nitro-phenyl)-3-oxo-1-phenyl-pent-4-enyl]-chromen-2-one

Conditions
ConditionsYield
With sodium hydroxide In water at 20℃;95%
warfarin
81-81-2

warfarin

4-chlorobenzaldehyde
104-88-1

4-chlorobenzaldehyde

4-hydroxy-3-[5-(4-chloro-phenyl)-3-oxo-1-phenyl-pent-4-enyl]-chromen-2-one
1189759-36-1

4-hydroxy-3-[5-(4-chloro-phenyl)-3-oxo-1-phenyl-pent-4-enyl]-chromen-2-one

Conditions
ConditionsYield
With sodium hydroxide In water at 20℃;93%
warfarin
81-81-2

warfarin

2-chloro-benzaldehyde
89-98-5

2-chloro-benzaldehyde

4-hydroxy-3-[5-(2-chloro-phenyl)-3-oxo-1-phenyl-pent-4-enyl]-chromen-2-one
1189759-37-2

4-hydroxy-3-[5-(2-chloro-phenyl)-3-oxo-1-phenyl-pent-4-enyl]-chromen-2-one

Conditions
ConditionsYield
With sodium hydroxide In water at 20℃;93%
warfarin
81-81-2

warfarin

4-nitrobenzaldehdye
555-16-8

4-nitrobenzaldehdye

4-hydroxy-3-[5-(4-nitro-phenyl)-3-oxo-1-phenyl-pent-4-enyl]-chromen-2-one
1189759-40-7

4-hydroxy-3-[5-(4-nitro-phenyl)-3-oxo-1-phenyl-pent-4-enyl]-chromen-2-one

Conditions
ConditionsYield
With sodium hydroxide In water at 20℃;93%
warfarin
81-81-2

warfarin

3-fluoro-3-(1-phenyl-3-oxobutyl)-2H-benzopyran-2,4-dione
910618-41-6

3-fluoro-3-(1-phenyl-3-oxobutyl)-2H-benzopyran-2,4-dione

Conditions
ConditionsYield
With N-fluorobis<(trifluoromethyl)sulfonyl>imide In chloroform; water at 35℃; for 0.25h;92%
poly(ethylene glycol), MW=2000, activated to carboxylic groups by succinic anhydride

poly(ethylene glycol), MW=2000, activated to carboxylic groups by succinic anhydride

warfarin
81-81-2

warfarin

A

warfarin conjugated with poly(ethylene glycol), MW=2000

warfarin conjugated with poly(ethylene glycol), MW=2000

B

1,3-Dicyclohexylurea
2387-23-7

1,3-Dicyclohexylurea

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide In dichloromethane at 20℃; for 5h;A 85%
B n/a
furfural
98-01-1

furfural

warfarin
81-81-2

warfarin

4-hydroxy-3-(5-furan-2-yl-3-oxo-1-phenyl-pent-4-enyl)-chromen-2-one
1253372-65-4

4-hydroxy-3-(5-furan-2-yl-3-oxo-1-phenyl-pent-4-enyl)-chromen-2-one

Conditions
ConditionsYield
With sodium hydroxide In water at 20℃;85%
warfarin
81-81-2

warfarin

benzaldehyde
100-52-7

benzaldehyde

4-hydroxy-3-(3-oxo-1,5-diphenyl-pent-4-enyl)-chromen-2-one
1189759-35-0

4-hydroxy-3-(3-oxo-1,5-diphenyl-pent-4-enyl)-chromen-2-one

Conditions
ConditionsYield
With sodium hydroxide In water at 20℃;85%
warfarin
81-81-2

warfarin

4-methoxy-benzaldehyde
123-11-5

4-methoxy-benzaldehyde

4-hydroxy-3-[5-(4-methoxy-phenyl)-3-oxo-1-phenyl-pent-4-enyl]-chromen-2-one
1189759-38-3

4-hydroxy-3-[5-(4-methoxy-phenyl)-3-oxo-1-phenyl-pent-4-enyl]-chromen-2-one

Conditions
ConditionsYield
With sodium hydroxide In water at 20℃;85%
warfarin
81-81-2

warfarin

potassium warfarin
2610-86-8

potassium warfarin

Conditions
ConditionsYield
With pyrographite; potassium hydroxide In water; isopropyl alcohol at 75℃; for 8h; pH=7.8 - 8; Product distribution / selectivity; Inert atmosphere;81%
warfarin
81-81-2

warfarin

Warfarin-oxim

Warfarin-oxim

Conditions
ConditionsYield
With pyridine; sodium hydroxide; hydroxylamine hydrochloride In ethanol 1) 12 h, 2) reflux, 6 h;77%
warfarin
81-81-2

warfarin

vanadium(IV) fluoride
10049-16-8

vanadium(IV) fluoride

difluorovanadium(IV)di(4-oxo-3-(oxo-1-phenylbutyl)2H-1-benzopyran-2-one)

difluorovanadium(IV)di(4-oxo-3-(oxo-1-phenylbutyl)2H-1-benzopyran-2-one)

Conditions
ConditionsYield
In methanol methanolic soln. of VF4 added to methanolic soln. of C19H16O4 dropwise with stirring, mixt. had pH 3, refluxed for 2 h, kept overnight with stirring at room temp.; solvent removed on a rotary apparatus under reduced pressure; recrystn. (MeOH/n-hexane, 1/1); elem. anal., detd. by thermal anal.;77%
warfarin
81-81-2

warfarin

1-oxyl-4-carboxyl-2,2,6,6-tetramethylpiperidine
37149-18-1

1-oxyl-4-carboxyl-2,2,6,6-tetramethylpiperidine

2-oxo-3-[(RS)-3-oxo-1-phenylbutyl]-2H-chromen-4-yl 2,2,6,6-tetramethylpiperidine-1-oxyl-4-carboxylate

2-oxo-3-[(RS)-3-oxo-1-phenylbutyl]-2H-chromen-4-yl 2,2,6,6-tetramethylpiperidine-1-oxyl-4-carboxylate

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide In dichloromethane; N,N-dimethyl-formamide at 0 - 20℃; for 26h; Inert atmosphere;75%
warfarin
81-81-2

warfarin

acetic anhydride
108-24-7

acetic anhydride

4-acetoxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one
5979-00-0

4-acetoxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one

Conditions
ConditionsYield
for 1h; Heating;71.4%
warfarin
81-81-2

warfarin

benzaldehyde
100-52-7

benzaldehyde

methylamine
74-89-5

methylamine

[3',4':5,6]pyrano[3,2-c]pyridine-6(7H)-one

[3',4':5,6]pyrano[3,2-c]pyridine-6(7H)-one

Conditions
ConditionsYield
In ethanol; water Heating; stereoselective reaction;68%
warfarin
81-81-2

warfarin

Benzyl bromoacetate
5437-45-6

Benzyl bromoacetate

C28H24O6

C28H24O6

Conditions
ConditionsYield
In acetone at 45℃; for 48h;65%
warfarin
81-81-2

warfarin

trifluoromethylsulfonic anhydride
358-23-6

trifluoromethylsulfonic anhydride

trifluoro-methanesulfonic acid 2-oxo-3-(3-oxo-1-phenyl-butyl)-2H-chromen-4-yl ester
929551-51-9

trifluoro-methanesulfonic acid 2-oxo-3-(3-oxo-1-phenyl-butyl)-2H-chromen-4-yl ester

Conditions
ConditionsYield
With triethylamine In chloroform at -5 - 25℃;62%
warfarin
81-81-2

warfarin

Trimethylboroxine
823-96-1

Trimethylboroxine

C20H18O4

C20H18O4

Conditions
ConditionsYield
With pentamethylcyclopentadienyl(benzene)cobalt(III) hexafluorophosphate; potassium carbonate; silver carbonate In 2-methyltetrahydrofuran at 60℃; for 16h; Inert atmosphere; Sealed tube;56%
methanol
67-56-1

methanol

warfarin
81-81-2

warfarin

2-methoxy-2-methyl-4-phenyl-3,4-dihydropyrano[3,2-c]chromen-5(2H)-one
518-20-7, 54288-87-8, 54288-88-9, 64753-99-7, 64754-00-3, 64754-01-4, 65207-43-4, 94902-10-0

2-methoxy-2-methyl-4-phenyl-3,4-dihydropyrano[3,2-c]chromen-5(2H)-one

2-methoxy-2-methyl-4-phenyl-3,4-dihydro-2H-pyrano[3,2-c]chromen-5-one

2-methoxy-2-methyl-4-phenyl-3,4-dihydro-2H-pyrano[3,2-c]chromen-5-one

Conditions
ConditionsYield
With hydrogenchloride for 23h; Reflux;A 53%
B 9%
warfarin
81-81-2

warfarin

benzyl bromide
100-39-0

benzyl bromide

C26H22O4

C26H22O4

Conditions
ConditionsYield
With potassium carbonate In acetone at 25℃; for 24h;38%
warfarin
81-81-2

warfarin

4'-Hydroxywarfarin
24579-14-4

4'-Hydroxywarfarin

Conditions
ConditionsYield
With culture of Cunninghamella bainieri In water for 144h; Product distribution; Ph7 phosphate buffer; metabolism of warfarin to 4'-hydroxywarfarin using the fungus Cunninghamella bainiery, possible mechanism of aromatic hydroxylation, primary isotope effect; inhibition of hydroxylation by CO;2 mg

81-81-2Relevant articles and documents

Ionic liquids: Efficient media for the lipase-catalyzed Michael addition

Fan, Yunchang,Cai, Dongxu,Wang, Xin,Yang, Lei

, (2018)

Recently, ionic liquids (ILs) have been regarded as ideal media for non-aqueous bio-catalysis. In this work, the synthesis of warfarin by the lipase-catalyzed Michael addition in IL media and the parameters that affected the warfarin yield were investigated. Experimental results demonstrated that the chemical structures of the ILs were a major factor for influencing the warfarin yield. The ILs containing the NTf2– anion were suitable reaction media due to the high chemical stability of this anion. The incorporation of the hydroxyl group on the IL cation significantly improved the lipase activity due to the H2O-mimicking property of this group. The lipase activity decreased by increasing the alkyl chain length on the IL cation due to the non-polar domain formation of the IL cation at the active site entrance of lipase. The ILs and lipase could be reused no less than five times without reduction in the warfarin yield.

Enzyme-catalyzed Michael addition for the synthesis of warfarin and its determination via fluorescence quenching of L-tryptophan

Yuan, Yusheng,Yang, Liu,Liu, Shaopu,Yang, Jidong,Zhang, Hui,Yan, Jingjing,Hu, Xiaoli

, p. 183 - 188 (2017)

A sensitive fluorescence sensor for warfarin was proposed via quenching the fluorescence of L-tryptophan due to the interaction between warfarin and L-tryptophan. Warfarin, as one of the most effective anticoagulants, was designed and synthesized via lipase from porcine pancreas (PPL) as a biocatalyst to catalyze the Michael addition of 4-hydroxycoumarin to α, β-unsaturated enones in organic medium in the presence of water. Furthermore, the spectrofluorometry was used to detect the concentration of warfarin with a linear range and detection limit (3σ/k) of 0.04–12.0?μmol?L??1 (R2?=?0.994) and 0.01?μmol?L??1, respectively. Herein, this was the first application of bio-catalytic synthesis and fluorescence for the determination of warfarin. The proposed method was applied to determine warfarin of the drug in tablets with satisfactory results.

Hypervalent Iodine(III)-Mediated Tosyloxylation of 4-Hydroxycoumarins

Xu, Bowen,Gao, Yiping,Han, Jianwei,Xing, Zejing,Zhao, Sihan,Zhang, Ziyang,Ren, Runlin,Wang, Limin

, p. 10136 - 10144 (2019)

An efficient approach was developed for synthesis of 3-tosyloxy-4-hydroxycoumarins under mild conditions by using Koser's reagents. The reaction tolerated various functional groups, and the products served as useful aromatic building blocks. Additionally, a plausible mechanism via iodonium ylide was proposed, and the oral anticoagulant Warfarin was synthesized in good yield.

Spectral assignments and structural studies of a warfarin derivative stereoselectively formed by tandem cyclization

Velayutham Pillai,Rajeswari,Vidhyasagar

, p. 447 - 454 (2015)

Abstract The structural elucidation of a Mannich condensation product of rac-Warfarin with benzaldehyde and methyl amine was carried out using IR, Mass, 1H NMR, 13C NMR, 1H-1H COSY, 1H-13C COSY, DEPT-135, HMBC, NOESY spectra and single crystal X-ray diffraction. Formation of a new pyran ring via a tandem cyclization in the presence of methyl amine was observed. The optimized geometry and HOMO-LUMO energy gap along with other important physical parameters were found by Gaussian 09 program using HF 6-31G (d, p) and B3YLP/DFT 6-31G (d, p) level of theory. The preferred conformation of the piperidine ring in solution state was found to be chair from the NMR spectra. Single crystal X-ray diffraction and optimized geometry (by theoretical study) also confirms the chair conformation in the solid state.

Primary Amine Catalyzed Activation of Carbonyl Compounds: A Study on Reaction Pathways and Reactive Intermediates by Mass Spectrometry

Bencivenni, Giorgio,Calcaterra, Andrea,Ciogli, Alessia,Iazzetti, Antonia,Mazzoccanti, Giulia,Righi, Paolo,Villani, Claudio

supporting information, (2021/12/01)

The field of organocatalysis is expanding at a fast pace. Its growth is sustained by major stimuli, such as the effort toward an understanding of the mechanisms of reaction and catalytic processes in general, the elucidation of basic properties leading to stereocontrol and the search for broad applicability and scalability of the synthetic methodology. This paper reports a thorough study based on ESI-MS spectrometry of amino-organocatalyzed model reactions under different experimental conditions. Off-line reaction monitoring of mixtures containing different catalytic systems, by ESI-MSn showed the presence of several putative intermediate species, either in their protonated or sodiated forms. In addition, enantioselective chromatography of crude reactions provides the stereochemical outcome of asymmetric reactions. The bulk of the data collected offers a clue of the intricate pathways occurring in solution for the studied reactions.

Enantioseparation of mandelic acid on vancomycin column: Experimental and docking study

Shahnani, Mostafa,Sefidbakht, Yahya,Maghari, Shokoofeh,Mehdi, Ahmad,Rezadoost, Hassan,Ghassempour, Alireza

supporting information, p. 1289 - 1298 (2020/08/19)

So far, no detailed view has been expressed regarding the interactions between vancomycin and racemic compounds including mandelic acid. In the current study, a chiral stationary phase was prepared by using 3-aminopropyltriethoxysilane and succinic anhydride to graft carboxylated silica microspheres and subsequently by activating the carboxylic acid group for vancomycin immobilization. Characterization by elemental analysis, Fourier transform infrared spectroscopy, solid-state nuclear magnetic resonance, and thermogravimetric analysis demonstrated effective functionalization of the silica surface. R and S enantiomers of mandelic acid were separated by the synthetic vancomycin column. Finally, the interaction between vancomycin and R/S mandelic acid enantiomers was simulated by Auto-dock Vina. The binding energies of interactions between R and S enantiomers and vancomycin chiral stationary phase were different. In the most probable interaction, the difference in mandelic acid binding energy was approximately 0.2 kcal/mol. In addition, circular dichroism spectra of vancomycin interacting with R and S enantiomers showed different patterns. Therefore, R and S mandelic acid enantiomers may occupy various binding pockets and interact with different vancomycin functions. These observations emphasized the different retention of R and S mandelic acid enantiomers in vancomycin chiral column.

The Synthesis of Warfarin Using a Reconfigurable-Reactor Platform Integrated to a Multiple-Variable Optimization Tool

Bizarri, Nour,Kwak, Jee Seong,Mallik, Debasis,Organ, Michael G.,Sharif, Sepideh,Zhang, Wenyao Peter

supporting information, p. 15505 - 15508 (2020/11/30)

Optimization of the asymmetric synthesis of warfarin, an important anticoagulant, has been evaluated using a reconfigurable reaction platform capable of performing batch, continuous flow, and plug-flow synthesis. Further, this platform has been integrated with a novel, multidimensional, multiple variable analysis tool that can evaluate multiple critical quality attributes (CQA), percent conversion and enantiomeric excess in this case, from a single injection that is repeatedly recycled in a closed loop of chromatography columns, a detector and a heart-cut valve. Further, the new, integrated analysis system also facilitates validation of each QA, providing a high-level of confidence in analytical measurements, which are obtained without operator intervention.

Enantioselective Michael Addition Reaction Catalysed by Enantiopure Binuclear Nickel(II) Close-Ended Helicates

Arunachalam, Rajendran,Chinnaraja, Eswaran,Natarajan, Ramalingam,Samanta, Krishanu,Subramanian, Palani S.

, (2020/02/04)

The enantiopure Ni(II) helicates [Ni2L1RR.Cl2] (1), [Ni2L1SS.Cl2] (1′), [Ni2L2RR.Cl2] (2), [Ni2L2SS.Cl2] (2′) were synthesized by one-pot self-assembly technique from R-(+)- or S-(?)-1,1′-binaphthyl-2,2′-diamine, with 4-methyl-2,6-diformyl phenol or 4-tert-butyl-2,6-diformyl phenol and nickel salts. This binuclear double stranded Ni(II) helicates were characterized by ESI-MS, IR and single crystal X-ray structure wherever applicable. The extensive chiroptical studies suggest that the complexes are enantiopure in nature. The chirality transfer from ligand L1RR & L2RR to Ni(II) metal centre produced ΔΔ geometrical chirality, while their enantiomeric counterpart L1SS & L2SS produced ΛΛ chirality in their respective complexes.These enantiopure helicates were applied as catalysts in asymmetric Michael addition of 1,3-dicarbonyl compounds with β-nitrostyrene to produce nitroalkanes in good yield (96–98%) and ee (78–94%). (Figure presented.).

Fe3O4?l-Proline/Pd nanocomposite for one-pot tandem catalytic synthesis of (±)-warfarin from benzyl alcohol: Synergistic action of organocatalyst and transition metal catalyst

Tomer, Sanjiv O.,Soni, Hemant P.

, p. 6517 - 6531 (2019/11/20)

One-pot synthesis of (±)-warfarin, an anticoagulant, has been achieved from benzyl alcohol in a 'green way' by using a multicomponent catalyst. For the purpose, l-proline capped Fe3O4 nanoparticles (Fe3O4?l-proline NPs) were synthesized and metallic palladium was loaded on its surface (Fe3O4?l-proline/Pd NCs). The morphology, particle size and shape were studied by using FESEM and TEM analysis. The Pd present on the surface was responsible for oxidation of benzyl alcohol and its derivatives to the corresponding aldehyde in situ. This in turn, condensed with acetone to form the aldol condensation product, benzylideneacetone, at 70 °C due to the presence of the l-proline organocatalyst on the surface of Fe3O4 NPs. Later, 4-hydroxycoumarin was introduced to condense with in situ generated benzylideneacetone by a Michael addition to form the target product (±)-warfarin. It was established that benzyl alcohol can be converted into the final product, (±)-warfarin, with an overall 35% yield within 5 days in a single-pot process. This process requires a rise in temperature in stages to a maximum of 100 °C and 1 atm pressure of dioxygen gas. An important aspect of the developed process is the avoidance of loss of costly Pd by leaching and catalyst recovery by the use of a magnetic field. The use of a solvent like PEG-400 makes the process green in a true sense. The interaction of l-proline with Fe3O4 NPs and the presence of Pd on the surface were confirmed by the FTIR and XRD patterns, respectively. The present study hereby suggests a combined 3-step mechanism for the production of the target product warfarin. Pilot-scale one-pot production of (±)-warfarin was carried out and a flow diagram with various unit processes is presented.

Warfarin hapten and artificial antigen, preparation method and application thereof

-

Paragraph 0060; 0061-0063, (2019/06/30)

The invention relates to warfarin hapten and artificial antigen, a preparation method and an application thereof. The structure of the warfarin hapten is shown in the formula (I) which is as shown inthe specification, wherein the warfarin artificial antigen is obtained by coupling hapten shown in the formula (I) with carrier protein. By using the warfarin artificial antigen to immunize animals, aspecific antibody with high titer and sensitivity can be obtained. The warfarin hapten and the antibody prepared by the warfarin hapten provide a new method for establishing a rapid, simple, cheap, sensitive and specific warfarin detection method.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 81-81-2